Orthofix Medical (NASDAQ:OFIX) Releases Quarterly Earnings Results

Orthofix Medical (NASDAQ:OFIX) announced its earnings results on Tuesday. The medical device company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.81), Zacks reports. Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. Orthofix Medical updated its FY 2025 guidance to EPS.

Orthofix Medical Stock Performance

NASDAQ:OFIX opened at $20.16 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The firm’s 50-day moving average is $17.94 and its 200-day moving average is $17.34. Orthofix Medical has a 52-week low of $12.08 and a 52-week high of $20.73. The company has a market cap of $770.20 million, a price-to-earnings ratio of -6.44 and a beta of 1.10.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Roth Mkm reissued a “buy” rating and issued a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Canaccord Genuity Group began coverage on shares of Orthofix Medical in a report on Wednesday, January 22nd. They set a “buy” rating and a $24.00 price target for the company. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research note on Friday, January 31st. Finally, Stifel Nicolaus raised shares of Orthofix Medical from a “hold” rating to a “buy” rating and lifted their price objective for the company from $18.00 to $24.00 in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Insider Buying and Selling

In other news, CFO Julie Andrews sold 4,655 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares of the company’s stock, valued at $506,501.68. This represents a 14.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Massimo Calafiore sold 9,203 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the sale, the chief executive officer now directly owns 124,151 shares in the company, valued at approximately $2,127,948.14. The trade was a 6.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,442 shares of company stock valued at $436,883 over the last three months. 2.60% of the stock is owned by corporate insiders.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.